Teva sues FDA on “authorized” generics
Executive Summary
FDA's position that "authorized" generics are procompetitive is economically baseless and goes beyond the agency's area of expertise, Teva says in a lawsuit. Company sues in D.C. federal court Aug. 20 seeking an order directing FDA to prohibit the sale of authorized or "brand" generics prior to the expiration of an ANDA first filer's 180-day generic marketing exclusivity. Mylan filed a similar lawsuit against FDA in Clarksburg, W.Va. federal court (1"The Pink Sheet" Aug. 23, 2004, p. 13)...
You may also be interested in...
Mylan Takes “Authorized” Generics Fight To Congress, FTC, Courts
Mylan is taking its fight against "authorized" generics beyond FDA to Capitol Hill, the Federal Trade Commission and the federal courts
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.